Vir Biotechnology, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Vir Biotechnology reported Q3 2026 net loss of $96.3M (vs. $163.1M in Q3 2025) with cash/investments of $901.3M as of Sept 30, 2026. Key catalysts: Phase 3 ECLIPSE 1 trial topline data expected Q4 2026 for chronic hepatitis delta combination therapy; VIR-5500 oncology asset achieved proof-of-concept and received FDA Fast Track designation with pivotal trials planned for 2027. Separately, Vir entered collaboration with Gilead: $90M upfront ($65M cash + $25M equity at 30% premium) plus up to $45M near-term preclinical milestones and up to $1.74B in development/regulatory/commercial milestones, with tiered royalties, for discovery and engineering of three novel PRO-XTEN dual-masked T-cell engagers.
Why this rating
Gilead deal ($90M upfront = 13% of market cap) provides meaningful near-term capital and validation; ECLIPSE 1 readout is pivotal but outcome unknown; VIR-5500 Fast Track positive. Cash runway extended to mid-2028.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.